{"id":63930,"date":"2025-01-24T00:01:27","date_gmt":"2025-01-24T00:01:27","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/01\/24\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/"},"modified":"2025-01-24T00:01:27","modified_gmt":"2025-01-24T00:01:27","slug":"abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/","title":{"rendered":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress"},"content":{"rendered":"<div>\n<p align=\"center\"><strong>Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress<\/strong><\/p>\n<p align=\"justify\"><strong>PARIS, France \u2013 January 23, 2025 \u2013 10:05 PM CET<\/strong> \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational, orally administered, once-daily small molecule] in clinical development for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at The European Crohn\u2019s and Colitis Organization\u2019s (ECCO\u2019s) 20th Annual Congress as part of scientific exchange, taking place February 19-22, 2025, in Berlin, Germany.<\/p>\n<p align=\"justify\"><em>\u201cWith 7 abstracts accepted for presentation at ECCO 2025, we look forward to our continued exchange with the inflammatory bowel disease community around the emerging clinical profile of obefazimod,\u201d<\/em> said <strong>Fabio Cataldi, MD, Chief Medical Officer of Abivax<\/strong>.<\/p>\n<p align=\"justify\">For more information, see congress details on the ECCO website, and visit the Abivax booth at the ECCO exhibitor hall (booth #30).<\/p>\n<p><strong>Obefazimod data to be presented:<\/strong><\/p>\n<table style=\"border-collapse: collapse; margin-left:1.1pt; width:551.35pt; border-collapse:collapse ;\">\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Presentation Title<\/strong><\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Session<\/strong><\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Presenter<\/strong><\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Presentation\/ Session Number<\/strong><\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Session Hall<\/strong><\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Date and Time (EDT)<\/strong><\/td>\n<\/tr>\n<tr>\n<td colspan=\"6\" style=\"width:735.14px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Oral Presentation<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">&#8220;Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD&#8221;<\/p>\n<\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Digital Oral Presentation Session 6<\/p>\n<\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Prof. Silvio Danese, MD, PhD<\/p>\n<p>Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Clinical Trials III<\/p>\n<\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hall A7<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><em>Friday, February 21, 2025 <\/em><\/p>\n<p><em>8:42am to 8:48am<\/p>\n<p><\/em><\/td>\n<\/tr>\n<tr>\n<td colspan=\"6\" style=\"width:735.14px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><strong>Poster Presentations<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">&#8220;Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study&#8221;<\/p>\n<\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Guided Poster Session<\/p>\n<\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fernando Magro, MD, PhD<\/p>\n<p>President-Elect of ECCO. Head of the Department of Clinical Pharmacology and Professor of Pharmacology and Therapeutics at University Hospital S\u00e3o Jo\u00e3o in Porto, Portugal<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Poster number: P0636<\/p>\n<\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hall 2.2<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Friday, February 21, 2025<\/p>\n<p><em>12:40pm to 1:40pm<\/p>\n<p><\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">&#8220;Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis&#8221;<\/p>\n<\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Guided Poster Session<\/p>\n<\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Prof. S\u00e9verine Vermeire, MD, PhD<\/p>\n<p>Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Poster number: P0813<\/p>\n<\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hall 2.2<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Friday, February 21, 2025<\/p>\n<p><em>12:40pm to 1:40pm<\/em><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">&#8220;Health-related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2 open-label maintenance study&#8221;<\/p>\n<\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Guided Poster Session<\/p>\n<\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Jennifer Fine, ScD<br \/>Head of HEOR, Abivax S. A<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Poster number: P0840<\/p>\n<\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hall 2.2<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Friday, February 21, 2025<\/p>\n<p><em>12:40pm to 1:40pm<\/p>\n<p><\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">&#8220;Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mg&#8221;<\/p>\n<\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Guided Poster Session<\/p>\n<\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Prof. Silvio Danese, MD, PhD<\/p>\n<p>Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">\u00a0<\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hall 2.2<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Friday, February 21, 2025<\/p>\n<p>12:40pm to 1:40pm<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">&#8220;Long-term treatment patterns, dose escalation, and steroid use among patients with moderate-to-severe ulcerative colitis using advanced therapies: 3 years of continuous follow-up using IQVIA PharMetrics Plus database&#8221;<\/p>\n<\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Guided Poster Session<\/p>\n<\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Prof. Parambir S. Dulai, M.D.<\/p>\n<p>Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">\u00a0<\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hall 2.2<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Friday, February 21, 2025<\/p>\n<p><em>12:40pm to 1:40pm<\/p>\n<p><\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"width:205.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">&#8220;Synergistic reduction of inflammatory cytokines with obefazimod and etrasimod in combination treatment vs. either monotherapy in a mouse model of inflammatory bowel disease&#8221;<\/p>\n<\/td>\n<td style=\"width:85.07px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Guided Poster Session<\/p>\n<\/td>\n<td style=\"width:122.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Didier Scherrer, PhD<br \/>Chief Scientific Officer<br \/>Abivax S.A.<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">\u00a0<\/td>\n<td style=\"width:56.67px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hall 2.2<\/p>\n<\/td>\n<td style=\"width:132.34px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Friday, February 21, 2025<\/p>\n<p><em>12:40pm to 1:40pm<\/p>\n<p><\/em><\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong><br \/>About Abivax <\/strong><\/p>\n<p align=\"justify\">Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax\u2019s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.<\/p>\n<p align=\"justify\"><strong>Contact:<\/strong><\/p>\n<p align=\"justify\">Patrick Malloy<br \/>SVP, Investor Relations<br \/>Abivax SA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PkTbt28bYdmZmqtiLGAi2vLXkb_Yd-rB29SghbkIsbYIs8cd0BtK5PyYvknWqObuMXEj-mHClJT31mJH71DSmvZ6yw1R0TgF0a_HeVm45itWENxE35843RmoRu6-iMXH\" rel=\"nofollow\" target=\"_blank\" title=\"patrick.malloy@abivax.com\">patrick.malloy@abivax.com<\/a><br \/>+1 847 987 4878<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/M2Q1NTU1NDUtMTU2MS00OTBmLThhNTgtN2EwZTRmNWExZDk2LTEwMzE2ODk=\/tiny\/Abivax.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress PARIS, France \u2013 January 23, 2025 \u2013 10:05 PM CET \u2013 Abivax SA (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing innovative therapies to address [&#8230;]\n","protected":false},"author":1,"featured_media":63931,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-63930","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress\" \/>\n<meta property=\"og:description\" content=\"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-24T00:01:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Abivax.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress\",\"datePublished\":\"2025-01-24T00:01:27+00:00\",\"dateModified\":\"2025-01-24T00:01:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/\",\"name\":\"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-01-24T00:01:27+00:00\",\"dateModified\":\"2025-01-24T00:01:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/","og_locale":"en_US","og_type":"article","og_title":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress","og_description":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual","og_url":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-01-24T00:01:27+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Abivax.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress","datePublished":"2025-01-24T00:01:27+00:00","dateModified":"2025-01-24T00:01:27+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/"},"wordCount":674,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/","url":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/","name":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-01-24T00:01:27+00:00","dateModified":"2025-01-24T00:01:27+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/abivax-announces-presentation-of-seven-abstracts-for-obefazimod-in-ulcerative-colitis-at-2025-european-crohns-and-colitis-organization-20th-annual-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn\u2019s and Colitis Organization 20th Annual Congress"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=63930"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63930\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/63931"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=63930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=63930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=63930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}